Company profile
ViaDerma, Inc.
OTC: VDRM · Healthcare · Drug Manufacturers - Specialty & Generic
#552 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 7GM —SS 45
v0.1 · 25/100 weight · pillars only
↑ operating margin, net margin · ↓ disclosure history, Piotroski F
Methodology →Revenue TTM
$600.9k
Rev growth YoY (TTM)
+2.5%
Net income (FY)
$2.7M
Employees
75
as of 2026-08-27
Market cap
$123.4k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$19.0M$19.0M2011
Net income$2.7M$2.7M2011
Operating income$4.0M$4.0M2011
Total assets$42.6M$42.6M2011
Liabilities$9.1M$9.1M2011
Equity$33.6M$33.6M2011
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ViaDerma, Inc.’s revenue?
ViaDerma, Inc. booked $19.0M in FY2011 revenue, contracting 29% year over year — slower than 75% of Healthcare companies we track, at a 14.1% net margin.
Peers · Healthcare
cbdMD, Inc.49DPrecision Optics Corporation, Inc.61CLENZ Therapeutics, Inc.48DQT Imaging Holdings, Inc.40DNephros, Inc.75B+Ethema Health Corporation57CNeighbors
Los Angeles →Key facts
CEOChristopher A Otiko
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersMarina del Rey, CA
ExchangeOTC: VDRM
Employees75
IPO date2014-10-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.